



## NEWS RELEASE

### Contacts:

Amanda Sheldon

Medtronic Public Relations

+1-818-576-4826

Jeff Warren

Medtronic Investor Relations

+1-763-505-2696

Michelle de Haaff

Glooko Public Relations

+1-650-533-0730

### FOR IMMEDIATE RELEASE

## MEDTRONIC EXPANDS ACCESS TO DIABETES DEVICE DATA THROUGH AGREEMENT WITH GLOOKO

*Medtronic Aims to Provide People with Diabetes, Their Care Teams and Healthcare Providers  
with Greater Insights to Improve Care*

**BOSTON – June 5, 2015** – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way. The partnership will incorporate information from Medtronic insulin pumps and continuous glucose monitors (CGM) into Glooko's secure, unified, cloud and mobile-based diabetes management platform. In addition, Medtronic will be able to integrate other health and wellness data sources, such as food, medication, fitness and biometric data with its CareLink platform. Combining this with insulin and CGM data could provide additional insights for patients and providers and could be beneficial to improve diabetes management.

Medtronic aims to provide holistic diabetes management solutions that optimize both clinical outcomes and health economics, which will rely on the safe and secure sharing of diabetes data across the care continuum. Both companies are exhibiting at American

Diabetes Association 75<sup>th</sup> Scientific Sessions: Medtronic at Booth #437 and Glooko at Booth #104.

Medtronic's decision support software, CareLink, has provided an incredible amount of compelling diabetes data along with an understanding of diabetes care pathways. Now, in addition to viewing insulin and glucose data through Medtronic's Carelink system, people with diabetes and their healthcare providers will also be able to access this information through Glooko, who will integrate it with other health data to offer a unified view to patients and their care teams to better make both day-to-day and longer term decisions. Glooko leverages mobile and web based views to organize all the information into consolidated analytics and insights that enable patients and healthcare providers to understand the impact of carbs and insulin, combined with other variables like exercise and biometric data.

"Our goal is to provide people with diabetes, their care teams and healthcare providers with actionable insights that improve decision-making to optimize care. By partnering with the Glooko diabetes management platform, we can provide safe and secure access to meaningful diabetes information to our customers that goes beyond just device data," said Annette Bröls, vice president and general manager, Diabetes Service and Solutions at Medtronic. "Combining the additional data collected by Glooko with our CareLink data will enable further insights into how various health and fitness activities affect insulin therapy. The Glooko partnership is part of our overall strategy to move towards a holistic diabetes management company and use our leading technologies, data and informatics to enable better therapy decision making and care for people with diabetes, to enable greater freedom and better health."

“Medtronic customers and their healthcare teams can leverage the Glooko unified platform to improve outcomes and reduce costs by leveraging mobile and cloud based technology to better understand and act on insights to improve their care plan and lifestyle,” said Rick Altinger, CEO of Glooko. “Working together we will bring information from Medtronic insulin pumps and continuous glucose monitors, along with food, medication, fitness and biometric data, to offer a unified view and actionable insights to patients and their care teams.”

With Medtronic data available in the Glooko diabetes management platform, healthcare systems will be able to provide more proactive care across the broadest set of patients. Glooko will also allow healthcare systems to identify blood glucose patterns that represent actions that can be improved (such as altering insulin bolus levels) or flagging at-risk patients among their patient population.

### **About Glooko**

Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at <http://www.glooko.com> and follow us at [Twitter.com/GlookoInc](https://twitter.com/GlookoInc) and [Facebook.com/Glooko](https://facebook.com/Glooko).

**About the Diabetes Group at Medtronic ([www.medtronicdiabetes.com](http://www.medtronicdiabetes.com))**

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

**About Medtronic**

Medtronic plc ([www.medtronic.com](http://www.medtronic.com)), headquartered in Dublin, Ireland, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

**Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.**

-end-